Mitapivat,
does it really help with Increased week-12-to-24 hemoglobin response in non-transfusion-dependent alpha- or beta-thalassemia?
research showsThe grade is C. ENERGIZE analyzed all 194 randomized patients in the full analysis set. A mean hemoglobin increase of at least 1.0 g/dL from weeks 12 through 24 occurred in 55/130 (42%) with mitapivat versus 1/64 (2%) with placebo, adjusted difference 41 points (95% CI 32-50), P<.0001. The difference is large, but the primary endpoint is a laboratory surrogate, the confirmatory evidence is one Agios-funded trial, and total enrollment was below 200, giving C with 50 points.
ads claimThe result should not be expanded to proven improvement in every anemia symptom or long-term complication. The established primary result is a 24-week hemoglobin laboratory response; fatigue, transfusion outcomes, clinical events, and long-term safety require separate reading.
Useful facts when choosing a product
- Mitapivat is an oral prescription activator of red-cell pyruvate kinase.
- Agios supplied mitapivat and matching placebo as trial treatment materials.
- The primary full analysis set included all 194 randomized patients; the safety set included 192 treated patients.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.mitapivat.oral.week-12-to-24-hemoglobin-response-in-non-transfusion-dependent-alpha-or-beta-thalassemia.increase.placeboUnknown > Mitapivat > Oral > week-12-to-24 hemoglobin response in non-transfusion-dependent alpha- or beta-thalassemia > Increase claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
This was a 24-week, 2:1 randomized, double-blind, placebo-controlled phase 3 trial at 70 hospitals in 18 countries, 130 versus 64. The prespecified full analysis set was ‘All subjects who are randomized,’ and all 194 entered the primary analysis. The protocol classified patients with fewer than two on-treatment hemoglobin assessments as nonresponders. The safety set included 192 treated patients, 129 versus 63. No interim analysis was planned, and recruitment and analysis completed without early stopping. Agios Pharmaceuticals fully funded the study, participated in design, collection, analysis, interpretation, and reporting, and employed multiple authors. The protocol states that the sponsor provided mitapivat and matched placebo. Separate company-supplied assessment tools were not identified. The one avoidable design limitation was a total sample below 200.
Why this is classified as C (50)
The 41-point hemoglobin-response difference is large, but a surrogate endpoint, one manufacturer-only trial, and a 194-person sample give C with 50 points.
Counterpoint. C does not mean hemoglobin failed to rise. It means a strong laboratory response alone does not establish long-term patient-important benefit.
Rejudgment record. Cross-check applied — Cross-checked ENERGIZE's all-194 full analysis set, hemoglobin-response definition and missing-data rule, manufacturer role and drug supply, 192-person safety set, and absence of interim analysis
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased 24-week hemoglobin response | C | Response was 42% versus 2%, adjusted difference 41 points. |
| Reduced long-term clinical complications | ? | A 24-week laboratory primary endpoint cannot establish long-term clinical-event reduction. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Taher AT et al. 2025 ENERGIZE | International 2:1 double-blind placebo-controlled phase 3 randomized trial | 194 randomized and in primary full analysis set, 130/64; safety 192, 129/63 | Fully funded by Agios Pharmaceuticals, which participated throughout and supplied study drug and matching placebo | Hemoglobin response defined as at least a 1.0-g/dL increase in mean hemoglobin from weeks 12 through 24 | 55/130 (42%) versus 1/64 (2%), adjusted difference 41 points (95% CI 32-50), P<.0001 | Single small manufacturer confirmatory trial with a surrogate endpoint |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-18).
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Mitapivat x hemoglobin response in non-transfusion-dependent thalassemia — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/mitapivat-non-transfusion-dependent-alpha-beta-thalassemia-hemoglobin-response/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.